Galmed Pharmaceuticals
GLMD
31 hedge funds and large institutions have $30.1M invested in Galmed Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 6 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
0.04% less ownership
Funds ownership: 0.2% → 0.17% (-0.04%)
9% less funds holding
Funds holding: 34 → 31 (-3)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
41% less capital invested
Capital invested by funds: $50.9M → $30.1M (-$20.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
II
Ibex Investors
Denver,
Colorado
|
+$823K |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$782K |
| 3 |
JP Morgan Chase
New York
|
+$180K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$127K |
| 5 |
WAM
Wealthspire Advisors (Maryland)
Potomac,
Maryland
|
+$75.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$7.14M |
| 2 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$4.69M |
| 3 |
PAM
Premier Asset Management
Chicago,
Illinois
|
-$572K |
| 4 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$337K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$180K |
GLMD Hedge Fund Activity: Q3 2019 in Review
31 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q3 2019, worth a combined $30.1M — down 41% from $50.9M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of GLMD and 4 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was Ibex Investors, adding an estimated $823K. The largest seller was Vivo Capital, exiting entirely with an estimated $7.14M sold.
- 31 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q3 2019, down from 34 in Q2 2019.
- Funds reported $30.1M of Galmed Pharmaceuticals stock for Q3 2019, down 41% quarter-over-quarter.
- 4 funds opened new Galmed Pharmaceuticals positions in Q3 2019 and 6 closed out, a net change of -2 holders.
- The largest Galmed Pharmaceuticals buyer in Q3 2019 was Ibex Investors, an estimated $823K added.
- The largest Galmed Pharmaceuticals seller in Q3 2019 was Vivo Capital, an estimated $7.14M sold.
Based on aggregated 13F filings for Q3 2019.